TreatSMA continues to work with NICE, NHSE and Biogen. We are seeking to expand inclusion if possible based on the recent appeal and campaign that TreatSMA and the community colaborated on together. TreatSMA and the community have made ITV News…
After sending additional information to the stakeholders, we have now proceeded with appealing the proposed nusinersen guidance and the Managed Access Agreement.
The clinicians and SMA community react to the draft nusinersen guidance
We are trying to find a way out of the MAA criteria, please stay tuned.
NICE is refusing to amend the entry criteria for Spinraza treatment. We are fighting on.
We have analysed the NICE/NHS eligibility criteria for Spinraza and we view them as potentially depriving hundreds of children and adults of access to the only treatment. Read on.
Closer to a new treatment: NICE has begun the appraisal process of SMA gene therapy Zolgensma.
NICE releases the final draft of the Managed Access Agreement. We will challenge some of the treatment criteria it proposes.